secwatch.observer — SEC 8-K summary
======================================

Issuer:     Design Therapeutics, Inc. (DSGN)
CIK:        0001807120
Form:       8-K
Filed at:   2021-11-09T23:59:59+00:00
Accession:  0000950170-21-003747
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Design Therapeutics reports Q3 2021 net loss $11.3M; FA program on track for H1 2022
--------------------------------------------------------------------------------

- Net loss $11.3M for Q3 2021; R&D expenses $8.5M, G&A $2.8M.
- Cash, cash equivalents and securities total $393.7M as of Sept 30, 2021.
- FA GeneTAC candidate on track for Phase 1 initiation in H1 2022; topline data expected in 2022.
- DM1 program: preclinical data show near-complete resolution of foci; clinical start planned for 2023.
- Company to present at Piper Healthcare Conference Nov 30 – Dec 2, 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1807120/000095017021003747/0000950170-21-003747-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1807120/000095017021003747/dsgn-20211109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-003747

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer